US4396628A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiviral activities of dansylcadaverine and closely related compounds
Assignee: United States Department of Health and Human Services
•
Filing: 1982-02-26
•
Granted: 1983-08-02
•
Expires: 2002-02-26
Abstract
Abstract The entry of animal viruses into their host cells proceeds via a specialized internalization pathway involving clathrin coated regions of the plasma membrane. In the present invention, there has been examined the effect of dansylcadaverine compared with amantadine and other antiviral agents as to the entry of vesicular stomatitis virus (VSV) into mouse cells. It was found that both compounds inhibit VSV entry. Both compounds inhibit the uptake of alpha 2macroglobulin ( alpha 2M), a protein that binds to specific membrane receptors and follows the same route of internalization. Dansylcadaverine is 20 fold more potent than amantadine to the blocking virus and also to the alpha 2macroglobulin uptake.
Inventors
- 👤 Ira H. Pastan
- 👤 Mark C. Willingham
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 06:36
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/18
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
51 words
A method of inhibiting and blocking the effective entry of vesicular stomatitis virus (VSV) and α 2 macroglobulin (α 2 M) into mouse cells comprising administering thereto an effective blockading amount of ##STR2## R 1 =--(CH 2 )-- 3-7 R 2 =--CH 3 R 3 =CH 3 in a pharmaceutically-acceptable carrier.
Claim 2
Independent Claim
51 words
A method of inhibiting and blocking the effective entry of vesicular stomatitis virus (VSV) and α 2 macroglobulin (α 2 M) into mouse cells comprising administering thereto an effective blockading amount of ##STR2## R 1 =--(CH 2 )-- 3-7 R 2 =--CH 3 R 3 =CH 3 in a pharmaceutically-acceptable carrier.
Claim 3
Dependent Claim
25 words
A method according to claim 1, wherein the compound utilized R 1 =--(CH 2 ) 5 , R 2 and R 3 =CH 3 .
Claim 4
Dependent Claim
20 words
A method according to claim 1, wherein the concentration of the compound utilized is about 50 μM to 500 μM.
References Cited (Backward Citations)
US4218476A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-01 | 1987-01-31 | 1987-08-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-01 | 1991-01-31 | 1991-08-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-01 | 1995-01-31 | 1995-08-02 | $7700.00 | Window Closed / Lapsed |